Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood thinner tested for COVID-19 clot prevention

NCT ID NCT07134738

Prevention Sponsor: Avexima Diol LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at whether a drug called Dimolegin can safely prevent blood clots in adults hospitalized with moderate COVID-19. A total of 184 participants took a 60 mg tablet once daily as part of their regular care. The main goal was to check for serious bleeding and other side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dimolegin (oral tablet, 60 mg once daily)
What this could lead to
If results are positive, Dimolegin could offer a new option to prevent dangerous blood clots in hospitalized COVID-19 patients.
What could go wrong
This was a small, non-interventional study without a comparison group, so it cannot prove effectiveness. The main risk was bleeding, which was closely monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

184 people

The number who actually took part.

Started

Jun 2024

Finished

Jan 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Hospitalized adult patients (≥18 years) with moderate COVID-19 requiring thromboprophylaxis.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Here's a concise English translation: * Voluntarily signed informed consent to participate in a non-interventional study. * Hospitalized patients with moderate COVID-19 requiring anticoagulant therapy for prevention of thrombotic complications. * Men and women aged ≥18 years. * Patients prescribed Dimolegin® 10 mg enteric-coated film tablets for thromboprophylaxis as part of routine care for moderate COVID-19. * Ability to understand study requirements, provide written consent and comply with protocol procedures. Exclusion Criteria: * Hypersensitivity to Dimolegin®. * Clinically significant active bleeding at screening. * Concomitant therapy with fibrinolytics or other anticoagulants. * Anemia or thrombocytopenia. * Thrombophilia. * Other coagulopathies or contraindications to anticoagulants. * Liver disease with impaired function or biliary tract disease. * Creatinine clearance \<30 mL/min. * Gastrointestinal disorders affecting absorption. * Pregnancy, breastfeeding, suspected pregnancy, or planned pregnancy within 3 months (including male patients whose partners plan pregnancy). * Use of investigational or unapproved drugs, or participation in another clinical study within 90 days before therapy start. * History or suspicion of alcohol or drug abuse, dependence, or addiction. * Any other condition that, in the investigator's opinion, could interfere with study participation or pose undue risk.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 thrombotic disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

  • Infectious Diseases Clinical Hospital No. 1

    Moscow, Russia

  • Infectious Diseases Hospital No. 2

    Sochi, Russia

  • Regional Clinical Hospital No. 3

    Chelyabinsk, Russia

  • Regional Infectious Diseases Clinical Hospital

    Yaroslavl, Russia

  • Republican Clinical Hospital named after Professor A.F. Agafonov

    Kazan', Russia

  • Tomsk Regional Hospital

    Tomsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.